Genentech, a member of the Roche Group, has extended its integrated drug discovery alliance with Evotec for three more years to discover novel small molecule therapeutics. No financial details were disclosed.   The collaboration began in May 2010 and was renewed in 2013. Evotec provides pharmacology, screening, chemistry, proteomics and structural biology services using its technology platform and drug discovery expertise.   Dr. Mario Polywka, chief operating officer of Evotec, said, “...